Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

KPV

gut-healthinflammation
Regulatory status — Research use only — not approved for human use

KPV (lysine-proline-valine) is a tripeptide derived from the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH), studied preclinically for its anti-inflammatory, mucosal-repair, and wound-healing properties [1][11][2]. The evidence base is composed entirely of in vitro and animal model studies — no human clinical trials, pharmacokinetic data, or regulatory approvals exist for KPV as a standalone agent. It is currently used in recreational and sport/bodybuilding communities despite an absence of human safety or efficacy data [8].

Evidence coverage

39/47 claims verified by independent fact-checker.

2 claims pending coverage
  • FDA prescribing-label data(1 claim)
  • Evidence tier below threshold(1 claim)

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
—
Typical dose
See research context
Route
multiple
Frequency
[insufficient evidence in research packet]
Cycle length
—
Evidence strength
Animal models

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • Half-life: — — dosed —.
  • Administered via multiple.
  • Evidence base: animal model studies.
  • Primary goals: gut-health, inflammation.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Primarily animal data

How we evaluate evidence →

How it works

BPC-157 acts on multiple parallel pathways — this multi-system action underlies its broad tissue repair profile.

KPV is a tripeptide (lysine-proline-valine) corresponding to residues 193–195 of α-melanocyte-stimulating hormone (α-MSH) and retains the parent molecule's anti-inflammatory signaling properties [1][2]. In vitro evidence indicates that KPV mitigates fine particulate matter (PM10)-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB signaling pathway [11]. Animal studies suggest KPV promotes mucosal barrier repair and restoration in inflamed colon tissue [9][13]. Mechanistic data point to KPV's classification among host defense peptides with combined antimicrobial and immunomodulatory properties relevant to inflammatory bowel disease [12]. Preclinical evidence also suggests that tripeptides including KPV regulate cell migration, proliferation, and differentiation while modulating inflammation in the wound-healing context [14]. In vitro work further shows that KPV and rapamycin (RAPA) can self-assemble into carrier-free nanodrugs, with preliminary preclinical data suggesting potential utility in vascular calcification models [15]. All mechanistic claims above derive from Tier 3 sources; no human pharmacological data exist.

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Evidence awareness
  • Understand that all KPV efficacy and safety data are from in vitro and animal studies only — no human trials exist.
  • Recognize that no FDA, EMA, or Health Canada approval or authorization exists for KPV as a standalone therapeutic.
Medical supervision
  • Discuss with a licensed physician before any use, given the complete absence of human safety data.
  • Disclose use to all treating clinicians, as drug interaction profiles are unknown.
Regulatory and anti-doping awareness
  • Athletes subject to anti-doping regulations should be aware that KPV use in sport contexts has been flagged as a potential doping concern [8].
  • Verify regulatory status of KPV in your jurisdiction before obtaining or using it.
  • No evidence-based preparation protocol exists for humans. Consult a qualified clinician before considering any use.
  • Baseline inflammatory markers or relevant clinical assessments cannot be recommended without human trial data to contextualize them.

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • No human protocol data exist to guide monitoring, dose adjustment, or duration of use.
  • Community use in sport and bodybuilding contexts has been noted [8], but these practices lack clinical validation.

After — Post-cycle

  • No cycling, washout, or post-cycle guidance can be derived from the available evidence base.

Stacks it appears in

KPV is typically used as a standalone compound. Stack data coming soon.

Related peptides

Other compounds indexed on Pepteligence that share research tags with KPV. Educational context only.

Thymosin Alpha-1

Tier 3
inflammation

BPC-157

Tier 3
inflammation

TB-500

Tier 3
inflammation

Safety

Common side effects

  • ·[insufficient evidence in research packet] No human adverse event data exist.

Rare side effects

  • ·[insufficient evidence in research packet]
Safety notice — Serious / theoretical risks:
  • [insufficient evidence in research packet] No human safety signals have been characterized. The absence of reported serious adverse events reflects the absence of human study, not confirmed safety.

Contraindications

  • ·[insufficient evidence in research packet] No human contraindication data exist. Use by competitive athletes may violate anti-doping regulations [8].

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for KPV. Be the first to share yours.

Share your experience →

Have you tried KPV?

Share your protocol and outcome to help build the community dataset.

Share your experience →

KPV — at a glance

PropertyKPV—
Half-life——
Routemultiple—
Typical doseSee research context—
MechanismKPV is a tripeptide (lysine-proline-valine) corresponding to residues 193–195 of α-melanocyte-stimulating hormone (α-MSH) and retains the parent molecule's anti-inflammatory signaling properties. In vitro evidence indicates that KPV mitigates fine particulate matter (PM10)-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB signaling pathway. Animal studies suggest KPV promotes mucosal barrier repair and restoration in inflamed colon tissue. Mechanistic data point to KPV's classification among host defense peptides with combined antimicrobial and immunomodulatory properties relevant to inflammatory bowel disease. Preclinical evidence also suggests that tripeptides including KPV regulate cell migration, proliferation, and differentiation while modulating inflammation in the wound-healing context. In vitro work further shows that KPV and rapamycin (RAPA) can self-assemble into carrier-free nanodrugs, with preliminary preclinical data suggesting potential utility in vascular calcification models. All mechanistic claims above derive from Tier 3 sources; no human pharmacological data exist.—
Evidence strengthanimalanecdotal
Primary goalgut-health—

Frequently asked questions

What is KPV?
KPV (lysine-proline-valine) is a tripeptide derived from the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH), studied preclinically for anti-inflammatory, mucosal-repair, and wound-healing properties. It is not FDA-approved and is classified as a research compound.
How does KPV work?
KPV corresponds to residues 193–195 of α-MSH and retains the parent molecule's anti-inflammatory signaling properties. In vitro evidence indicates it mitigates fine particulate matter–induced keratinocyte apoptosis and inflammation. These mechanistic findings come from preclinical research — no human trial data validate these pathways.
What is KPV used for?
Preclinical research has investigated KPV for anti-inflammatory effects at mucosal and skin surfaces, as well as wound healing. These findings come from in vitro and animal models. No controlled human clinical trials have established efficacy or safety for any indication.
Is KPV FDA-approved?
No. KPV is not FDA-approved for any indication. It is classified as a research compound with no established human safety or efficacy data.
What are common dosages of KPV?
No human clinical dosing data exist for KPV. No validated dose or frequency could be identified from the available research literature.
How is KPV administered?
KPV has been studied via multiple routes in preclinical research, including topical and mucosal routes. No administration route has been validated for safety or efficacy in controlled human trials.
What are common side effects of KPV?
No controlled human clinical trial data exist to characterize KPV's side-effect profile. Its safety in humans is not established.
Are there safety concerns with KPV?
No human contraindication data have been identified for KPV. The absence of human safety data means no definitive conclusions about safety in any clinical population can be drawn.
Is KPV prohibited in competitive sports?
KPV use by competitive athletes may violate anti-doping regulations. Athletes subject to WADA or equivalent anti-doping authority testing should verify KPV's prohibited status before use.
Is KPV legal?
KPV is not FDA-approved and is not a scheduled controlled substance in the United States. Its legal status for possession and sale varies by jurisdiction. This is not legal advice.
Can KPV be combined with other peptides?
No evidence-supported combination protocols have been established for KPV. The current source literature does not document any stacking combinations with human-validated data.
What does the research on KPV show overall?
KPV's research base consists of in vitro and preclinical studies focused on anti-inflammatory and mucosal repair properties derived from its structural relationship to α-MSH. No controlled human clinical trials have been conducted, making extrapolation to human outcomes premature.

References

  1. [1]

    NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development.

    Zeng Ke, Zhu Yuqi, Han Zhongxin et al.

    Cell death and differentiation · 2026 · PMID 40935835

    View on PubMed →
  2. [2]

    Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.

    Sun Jie, Xue Pengpeng, Liu Jiayi et al.

    ACS biomaterials science & engineering · 2021 · PMID 34547895

    View on PubMed →
  3. [3]

    PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced Colitis.

    Zhang Daifang, Jiang Longqi, Yu Fengxu et al.

    Frontiers in pharmacology · 2024 · PMID 39211778

    View on PubMed →
  4. [4]

    A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment.

    Marotti Valentina, Xu Yining, Bohns Michalowski Cécilia et al.

    Bioactive materials · 2024 · PMID 37859689

    View on PubMed →
  5. [5]

    Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing.

    Zhao Yingzheng, Huang Lantian, Lin Gaolong et al.

    International journal of biological macromolecules · 2022 · PMID 36240893

    View on PubMed →
  6. [6]

    In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis.

    Shao Weifeng, Chen Rui, Lin Gaolong et al.

    Biomaterials science · 2021 · PMID 34846053

    View on PubMed →
  7. [7]

    Biomimetic Melanosomes Promote Orientation-Selective Delivery and Melanocyte Pigmentation in the H2O2-Induced Vitiligo Mouse Model.

    Sun Ming-Chen, Xu Xiao-Ling, Du Yan et al.

    ACS nano · 2021 · PMID 34662120

    View on PubMed →
  8. [8]

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

    Coutinho Luis F D, DE Oliveira Neves Lucas F, Camilo Rafael P

    The Journal of sports medicine and physical fitness · 2026 · PMID 41880199

    View on PubMed →
  9. [9]

    A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.

    Zhao Yingzheng, Xue Pengpeng, Lin Gaolong et al.

    Acta biomaterialia · 2022 · PMID 35245681

    View on PubMed →
  10. [10]

    Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.

    Cheng Juan, Wu Peng, Li Chenwen et al.

    Science advances · 2026 · PMID 41533788

    View on PubMed →
  11. [11]

    Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.

    Sung Junghee, Ju Seo-Young, Park SeungHyun et al.

    Tissue & cell · 2025 · PMID 40073467

    View on PubMed →
  12. [12]

    Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.

    Rodrigues Júlia Morales, Ferreira Leal Ana Paula, Buccini Danieli Fernanda et al.

    Drug discovery today · 2025 · PMID 41241376

    View on PubMed →
  13. [13]

    Growth Factors-Loaded Temperature-Sensitive Hydrogel as Biomimetic Mucus Attenuated Murine Ulcerative Colitis via Repairing the Mucosal Barriers.

    Li Dingwei, Shangguan Jianxun, Yu Fengnan et al.

    ACS applied materials & interfaces · 2024 · PMID 38289234

    View on PubMed →
  14. [14]

    Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.

    Adnan Siti Balqis, Maarof Manira, Fauzi Mh Busra et al.

    International journal of medical sciences · 2025 · PMID 41209547

    View on PubMed →
  15. [15]

    KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.

    Zhang Li, Li Dongze, Aierken Yierpani et al.

    Advanced healthcare materials · 2024 · PMID 39252648

    View on PubMed →